Medicare Price Inflation Penalties Unlikely To Spur Greater Price Increases, Study Suggests
Executive Summary
Results of an analysis published in JAMA could undercut arguments against legislative proposals establishing inflation penalties in Medicare.
You may also be interested in...
Drug Pricing Bill: Senate Sponsors ‘Not Backing Down’ From Inflation Rebates
Price inflation rebates are the linchpin of the legislation’s Democratic support, Sen. Chuck Grassley, R-IA, argues. But to many Republicans, they sound too much like price controls.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.
Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?
Insurance plans put on notice that CMS is concerned about restrictions on drugs with negotiated prices, but it’s not clear what the agency can or will do about it.